FACTORES DE RIESGO Y LA RELACIÓN DE LAS INTERLEUCINAS 1β, 6 Y 8 EN LA APARICIÓN DE LA CONDICIÓN POST-COVID: UNA REVISIÓN SISTEMÁTICA CON METAANÁLISIS
DOI:
https://doi.org/10.66104/ybqxd808Palabras clave:
Biomarcadores, enfermedad post-COVID, COVID persistente, marcadores inflamatorios, salud públicaResumen
La condición post-COVID (PCC) se caracteriza por la persistencia de síntomas después de la infección aguda por SARS-CoV-2 y se asocia con mecanismos inflamatorios sostenidos. Esta revisión sistemática con metaanálisis evaluó los niveles de IL-1β, IL-6 e IL-8 en individuos con PCC, comparándolos con controles sanos e individuos recuperados sin síntomas persistentes. El protocolo se registró en PROSPERO (CRD42024610712) y se realizó de acuerdo con las directrices PRISMA 2020. Se incluyeron estudios observacionales que evaluaron las concentraciones séricas o plasmáticas de estas citocinas. La calidad metodológica se analizó utilizando instrumentos validados, y la diferencia de medias estandarizada (DME) con IC del 95% se estimó utilizando modelos de efectos fijos o aleatorios. Se incluyeron veinticinco estudios, con un total de 3927 participantes. Los individuos con PCC presentaron niveles significativamente más altos de IL-1β, IL-6 e IL-8 en comparación con los controles sanos. En comparación con los individuos recuperados, solo la IL-1β permaneció significativamente elevada. Los análisis de subgrupos sugirieron una influencia de la edad y la gravedad de la infección aguda. Los hallazgos respaldan la hipótesis de inflamación persistente en la enfermedad crónica post-COVID (ECP), destacando la IL-1β como un biomarcador potencial asociado con la persistencia sintomática.
Descargas
Referencias
ACOSTA-AMPUDIA, Y. et al. Persistent Autoimmune Activation and Proinflammatory State in Post-Coronavirus Disease 2019 Syndrome. The Journal of Infectious Diseases, [S. l.], v. 225, n. 12, p. 2155–2162, 15 jun. 2022. Disponível em: https://doi.org/10.1093/infdis/jiac017. Acesso em: 11 abr. 2025.
AID, M. et al. Long COVID involves activation of proinflammatory and immune exhaustion pathways. Nature Immunology, [S. l.], v. 27, n. 1, p. 61–71, jan. 2026. Disponível em: https://www.nature.com/articles/s41590-025-02353-x. Acesso em: 23 fev. 2026.
AKBAR, A. N.; GILROY, D. W. Aging immunity may exacerbate COVID-19. Science, [S. l.], New York, N.Y., v. 369, n. 6501, p. 256–257, 17 jul. 2020.
AL-HAKEIM, H. K. et al. Chronic Fatigue, Depression and Anxiety Symptoms in Long COVID Are Strongly Predicted by Neuroimmune and Neuro-Oxidative Pathways Which Are Caused by the Inflammation during Acute Infection. Journal of Clinical Medicine, [S. l.], v. 12, n. 2, p. 511, 8 jan. 2023. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC9865328/. Acesso em: 10 jan. 2026.
ALONSO-DOMÍNGUEZ, J. et al. High Levels of IL-1β, TNF-α and MIP-1α One Month after the Onset of the Acute SARS-CoV-2 Infection, Predictors of Post COVID-19 in Hospitalized Patients. Microorganisms, [S. l.], v. 11, n. 10, p. 2396, 26 set. 2023. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC10609568/. Acesso em: 10 jan. 2026.
ANANG, V. et al. SARS-CoV-2 innate immune recognition and implications for respiratory health. Cytokine & Growth Factor Reviews, [S. l.], v. 86, p. 167–180, dez. 2025.
BALDUZZI, S.; RÜCKER, G.; SCHWARZER, G. How to perform a meta-analysis with R: a practical tutorial. BMJ Mental Health, [S. l.], v. 22, n. 4, 23 out. 2019. Disponível em: https://mentalhealth.bmj.com/content/22/4/153. Acesso em: 9 maio 2025.
BERGANTINI, L. et al. Altered serum concentrations of IL-8, IL-32 and IL-10 in patients with lung impairment 6 months after COVID-19. Immunobiology, [S. l.], v. 229, n. 4, p. 152813, 1 jul. 2024. Disponível em: https://www.sciencedirect.com/science/article/pii/S0171298524000317. Acesso em: 10 jan. 2026.
BRASIL. Coronavírus Brasil - Ministério da Saúde. 2025. Disponível em: https://covid.saude.gov.br/. Acesso em: 11 set. 2024.
CAWLEY, A. Biomarker analysis. Drug Testing and Analysis, [S. l.], v. 14, n. 5, p. 791–793, 2022. Disponível em: https://onlinelibrary.wiley.com/doi/abs/10.1002/dta.3268. Acesso em: 1 ago. 2024.
CERVIA, C. et al. Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nature Communications, [S. l.], v. 13, n. 1, p. 446, 25 jan. 2022. Disponível em: https://www.nature.com/articles/s41467-021-27797-1. Acesso em: 10 jan. 2026.
CORREIA, A. O. et al. Neurological manifestations of COVID-19 and other coronaviruses: A systematic review. Neurology, Psychiatry, and Brain Research, [S. l.], v. 37, p. 27–32, set. 2020.
DANI, M. et al. Autonomic dysfunction in “long COVID”: rationale, physiology and management strategies. Clinical Medicine, [S. l.], London, England, v. 21, n. 1, p. e63–e67, jan. 2021.
DAVIS, H. E. et al. Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology, [S. l.], v. 21, n. 3, p. 133–146, mar. 2023. Disponível em: https://www.nature.com/articles/s41579-022-00846-2. Acesso em: 23 fev. 2026.
DE GRANDA-ORIVE, J. I.; SOLANO-REINA, S.; JIMÉNEZ-RUIZ, C. A. Are Smoking and Vaping Risk Factors of Developing Long and Persistent Post-COVID-19? Open Respiratory Archives, [S. l.], v. 4, n. 4, p. 100195, 1 out. 2022. Disponível em: https://www.sciencedirect.com/science/article/pii/S2659663622000418. Acesso em: 2 jun. 2025.
DEEKS, J. et al. Chapter 10: Chapter 10: Analysing data and undertaking meta-analyses. nov. 2024. Cochrane Handbook for Systematic Reviews of Interventions. Disponível em: https://training.cochrane.org/handbook/current/chapter-10. Acesso em: 8 maio 2025. (version 6.5.).
DUINDAM, H. B. et al. Systemic inflammation relates to neuroaxonal damage associated with long-term cognitive dysfunction in COVID-19 patients. Brain, Behavior, and Immunity, [S. l.], v. 117, p. 510–520, mar. 2024.
ELY, E. W.; BROWN, L. M.; FINEBERG, H. V. Long Covid Defined. New England Journal of Medicine, [S. l.], v. 391, n. 18, p. 1746–1753, 6 nov. 2024. Disponível em: https://www.nejm.org/doi/full/10.1056/NEJMsb2408466. Acesso em: 27 fev. 2025.
FERREIRA, A. C. et al. SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes. Cell Death Discovery, [S. l.], v. 7, n. 1, p. 43, 1 mar. 2021.
FERREIRA, A. M. S. et al. Symptoms and Risk Factors for Long COVID: A Cross-Sectional Study in Primary Care. Journal of Medical Virology, [S. l.], v. 97, n. 9, p. e70579, 2025. Disponível em: https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.70579. Acesso em: 19 fev. 2026.
FISCHER, C. et al. SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition. NPJ Vaccines, [S. l.], v. 9, p. 23, 5 fev. 2024. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC10844289/. Acesso em: 10 jan. 2026.
FRANCESCHI, C. et al. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nature Reviews. Endocrinology, [S. l.], v. 14, n. 10, p. 576–590, out. 2018.
GANESH, R. et al. The Female-Predominant Persistent Immune Dysregulation of the Post-COVID Syndrome. Mayo Clinic Proceedings, [S. l.], v. 97, n. 3, p. 454–464, 1 mar. 2022. Disponível em: https://www.mayoclinicproceedings.org/article/S0025-6196(21)00888-0/fulltext. Acesso em: 10 jan. 2026.
GOMES, S. M. R. et al. High levels of pro-inflammatory SARS-CoV-2-specific biomarkers revealed by in vitro whole blood cytokine release assay (CRA) in recovered and long-COVID-19 patients. PLOS ONE, [S. l.], v. 18, n. 4, p. e0283983, 5 abr. 2023. Disponível em: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0283983. Acesso em: 10 jan. 2026.
GREENHALGH, T. et al. Long COVID: a clinical update. The Lancet, [S. l.], v. 404, n. 10453, p. 707–724, 17 ago. 2024. Disponível em: https://www.sciencedirect.com/science/article/pii/S014067362401136X. Acesso em: 8 nov. 2024.
GUARIENTI, F. A. et al. COVID-19: a multi-organ perspective. Frontiers in Cellular and Infection Microbiology, [S. l.], v. 14, 18 out. 2024. Disponível em: https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2024.1425547/full. Acesso em: 11 mar. 2025.
HAWLEY, H. B. Long COVID: Clinical Findings, Pathology, and Endothelial Molecular Mechanisms. The American Journal of Medicine, [S. l.], v. 138, n. 1, p. 91–97, 1 jan. 2025. Disponível em: https://www.sciencedirect.com/science/article/pii/S0002934323005399. Acesso em: 11 mar. 2025.
HURME, A. et al. Post-COVID-19 condition in prospective inpatient and outpatient cohorts. Scientific Reports, [S. l.], v. 15, p. 6925, 26 fev. 2025. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC11865615/. Acesso em: 10 jan. 2026.
KENJI SUDO, F. et al. Cognitive, behavioral, neuroimaging and inflammatory biomarkers after hospitalization for COVID-19 in Brazil. Brain, Behavior, and Immunity, [S. l.], v. 115, p. 434–447, 1 jan. 2024. Disponível em: https://www.sciencedirect.com/science/article/pii/S0889159123003185. Acesso em: 10 jan. 2026.
LEMOS, F. F. B. et al. Prognostic significance of cytokine dysregulation in critically ill COVID-19 patients. Cytokine, [S. l.], v. 187, p. 156867, 1 mar. 2025. Disponível em: https://www.sciencedirect.com/science/article/pii/S1043466625000146. Acesso em: 27 fev. 2025.
LÓPEZ-SAMPALO, A.; BERNAL-LÓPEZ, M. R.; GÓMEZ-HUELGAS, R. Persistent COVID-19 syndrome. A narrative review. Revista Clínica Española (English Edition), [S. l.], v. 222, n. 4, p. 241–250, 1 abr. 2022. Disponível em: https://www.sciencedirect.com/science/article/pii/S225488742200008X. Acesso em: 11 mar. 2025.
LU, S. et al. Early biological markers of post-acute sequelae of SARS-CoV-2 infection. Nature Communications, [S. l.], v. 15, p. 7466, 29 ago. 2024. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC11358427/. Acesso em: 10 jan. 2026.
MAKI, F. M.; AL-THWANI, A. N.; JIAD, K. S. Study of some immunological signatures and their association with COVID-19 in a sample of recovered Iraqi patients. Immunobiology, [S. l.], v. 228, n. 2, p. 152348, 1 mar. 2023. Disponível em: https://www.sciencedirect.com/science/article/pii/S0171298523000165. Acesso em: 10 jan. 2026.
MCELVANEY, O. J. et al. Characterization of the Inflammatory Response to Severe COVID-19 Illness. American Journal of Respiratory and Critical Care Medicine, [S. l.], v. 202, n. 6, p. 812–821, 15 set. 2020.
MENEZES, D. C. de et al. Metabolic Profile of Patients with Long COVID: A Cross-Sectional Study. Nutrients, [S. l.], v. 15, n. 5, p. 1197, jan. 2023. Disponível em: https://www.mdpi.com/2072-6643/15/5/1197. Acesso em: 7 ago. 2024.
MENIAILO, M. E. et al. Interleukin-8 favors pro-inflammatory activity of human monocytes/macrophages. International Immunopharmacology, [S. l.], v. 56, p. 217–221, mar. 2018.
MROUEH, A. et al. COVID-19 promotes endothelial dysfunction and thrombogenicity: role of proinflammatory cytokines/SGLT2 prooxidant pathway. Journal of Thrombosis and Haemostasis, [S. l.], v. 22, n. 1, p. 286–299, 1 jan. 2024. Disponível em: https://www.jthjournal.org/article/S1538-7836(23)00724-9/fulltext. Acesso em: 10 jan. 2026.
MUELLER, M. R. et al. Long COVID: emerging pathophysiological mechanisms. Minerva medica, [S. l.], v. 116, n. 2, p. 156–165, 1 abr. 2025. Disponível em: https://doi.org/10.23736/S0026-4806.25.09539-4. Acesso em: 23 fev. 2026.
MÜLLER, L.; DI BENEDETTO, S. Immunosenescence and inflammaging: Mechanisms and modulation through diet and lifestyle. Frontiers in Immunology, [S. l.], v. 16, 4 dez. 2025. Disponível em: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1708280/full. Acesso em: 23 fev. 2026.
MUNN, Z. et al. Assessing the risk of bias of quantitative analytical studies: introducing the vision for critical appraisal within JBI systematic reviews. JBI Evidence Synthesis, [S. l.], v. 21, n. 3, p. 467, mar. 2023. Disponível em: https://journals.lww.com/jbisrir/fulltext/2023/03000/assessing_the_risk_of_bias_of_quantitative.2.aspx. Acesso em: 20 mar. 2025.
NALBANDIAN, A. et al. Post-acute COVID-19 syndrome. Nature Medicine, [S. l.], v. 27, n. 4, p. 601–615, abr. 2021. Disponível em: https://www.nature.com/articles/s41591-021-01283-z. Acesso em: 23 fev. 2026.
NIKKHOO, B. et al. Elevated interleukin (IL)-6 as a predictor of disease severity among Covid-19 patients: a prospective cohort study. BMC infectious diseases, [S. l.], v. 23, n. 1, p. 311, 9 maio 2023.
OUZZANI, M. et al. Rayyan—a web and mobile app for systematic reviews. Systematic Reviews, [S. l.], v. 5, n. 1, p. 210, 5 dez. 2016. Disponível em: https://doi.org/10.1186/s13643-016-0384-4. Acesso em: 20 jan. 2026.
PAGE, M. J. et al. [The PRISMA 2020 statement: an updated guideline for reporting systematic reviewsDeclaración PRISMA 2020: una guía actualizada para la publicación de revisiones sistemáticas]. Revista Panamericana De Salud Publica = Pan American Journal of Public Health, [S. l.], v. 46, p. e112, 2022.
PATTERSON, B. K. et al. Immune-Based Prediction of COVID-19 Severity and Chronicity Decoded Using Machine Learning. Frontiers in Immunology, [S. l.], v. 12, 28 jun. 2021. Disponível em: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.700782/full. Acesso em: 10 jan. 2026.
PELUSO, M. J. et al. Plasma Markers of Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-CoV-2 Infection. Neurology Neuroimmunology & Neuroinflammation, [S. l.], v. 9, n. 5, p. e200003, set. 2022. Disponível em: https://www.neurology.org/doi/10.1212/NXI.0000000000200003. Acesso em: 10 jan. 2026.
PHETSOUPHANH, C. et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nature Immunology, [S. l.], v. 23, n. 2, p. 210–216, fev. 2022.
POPA, E. et al. The Molecular Mechanisms of Cognitive Dysfunction in Long COVID: A Narrative Review. International Journal of Molecular Sciences, [S. l.], v. 26, n. 11, p. 5102, 26 maio 2025.
PROAL, A. D.; VANELZAKKER, M. B. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. Frontiers in Microbiology, [S. l.], v. 12, p. 698169, 2021.
QIAN, G.; MAHDI, A. Sensitivity analysis methods in the biomedical sciences. Mathematical Biosciences, [S. l.], v. 323, p. 108306, maio 2020.
RODRIGUES, R. S. et al. Increased Lung Immune Metabolic Activity in COVID-19 Survivors. Clinical Nuclear Medicine, [S. l.], v. 47, n. 12, p. 1019, dez. 2022. Disponível em: https://journals.lww.com/nuclearmed/abstract/2022/12000/increased_lung_immune_metabolic_activity_in.2.aspx. Acesso em: 10 jan. 2026.
RODRIGUES, T. S. et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. The Journal of Experimental Medicine, [S. l.], v. 218, n. 3, p. e20201707, 1 mar. 2021.
SANTANA-DE ANDA, K. et al. Novel Clinical, Immunological, and Metabolic Features Associated with Persistent Post-Acute COVID-19 Syndrome. International Journal of Molecular Sciences, [S. l.], v. 25, n. 17, p. 9661, 6 set. 2024. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC11395921/. Acesso em: 10 jan. 2026.
SBIERSKI-KIND, J. et al. Persistent immune abnormalities discriminate post-COVID syndrome from convalescence. Infection, [S. l.], v. 52, n. 3, p. 1087–1097, 1 jun. 2024. Disponível em: https://doi.org/10.1007/s15010-023-02164-y. Acesso em: 10 jan. 2026.
SCHULTHEISS, C. et al. The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Reports Medicine, [S. l.], v. 3, n. 6, p. 100663, 21 jun. 2022. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC9214726/. Acesso em: 10 jan. 2026.
SEKAR, P. et al. Post-COVID-19 Complications: A Study on Long COVID Symptoms and Their Pathophysiology. Journal of Pharmacy & Bioallied Sciences, [S. l.], v. 17, n. Suppl 3, p. S2557–S2559, set. 2025. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC12563606/. Acesso em: 10 jan. 2026.
SERAPIDE, F. et al. Lights and Shadows of Long COVID: Are Latent Infections the Real Hidden Enemy? Journal of Clinical Medicine, [S. l.], v. 13, n. 23, p. 7124, 25 nov. 2024.
SHEN, X.-L. et al. Clinical features and predictive nomogram for fatigue sequelae in non-severe patients infected with SARS-CoV-2 Omicron variant in Shanghai, China. Brain, Behavior, & Immunity - Health, [S. l.], v. 42, p. 100889, 18 out. 2024. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC11532739/. Acesso em: 10 jan. 2026.
SU, Y. et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell, [S. l.], v. 185, n. 5, p. 881-895.e20, 3 mar. 2022.
TANG, N. et al. Blood Markers Show Neural Consequences of LongCOVID-19. Cells, [S. l.], v. 13, n. 6, p. 478, 8 mar. 2024. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC10969290/. Acesso em: 10 jan. 2026.
TEIXEIRA, E. P.; LYNN, F. A.; SOUZA, M. de L. de. GUIA PARA REVISÃO SISTEMATICA DE ESTUDOS OBSERVACIONAIS. Texto & Contexto - Enfermagem, [S. l.], v. 33, p. e20230221, 13 maio 2024. Disponível em: https://www.scielo.br/j/tce/a/876BLxXM3XxsXZTwGXSKCKM/?lang=pt&utm_source=chatgpt.com. Acesso em: 12 mar. 2025.
TORKI, E. et al. The demographic, laboratory and genetic factors associated with long Covid-19 syndrome: a case–control study. Clinical and Experimental Medicine, [S. l.], v. 24, n. 1, p. 1, 2024. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC10794331/. Acesso em: 10 jan. 2026.
VALENTE CORONEL, P. M. et al. Involvement of oxidative stress in post-acute sequelae of COVID-19: clinical implications. Redox Report: Communications in Free Radical Research, [S. l.], v. 30, n. 1, p. 2471738, dez. 2025.
WAN, X. et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC medical research methodology, [S. l.], v. 14, p. 135, 19 dez. 2014.
WANG, K. et al. Sequential multi-omics analysis identifies clinical phenotypes and predictive biomarkers for long COVID. Cell Reports Medicine, [S. l.], v. 4, n. 11, p. 101254, 21 nov. 2023. Disponível em: https://www.sciencedirect.com/science/article/pii/S2666379123004317. Acesso em: 10 jan. 2026.
YANG, S.-R. et al. Cigarette smoke induces proinflammatory cytokine release by activation of NF-kappaB and posttranslational modifications of histone deacetylase in macrophages. American Journal of Physiology. Lung Cellular and Molecular Physiology, [S. l.], v. 291, n. 1, p. L46-57, jul. 2006.
YASEEN, M. M.; ABUHARFEIL, N. M.; DARMANI, H. The role of IL-1β during human immunodeficiency virus type 1 infection. Reviews in Medical Virology, [S. l.], v. 33, n. 1, p. e2400, 2023. Disponível em: https://onlinelibrary.wiley.com/doi/abs/10.1002/rmv.2400. Acesso em: 2 jun. 2025.
ZHANG, J. et al. In-depth analysis of the risk factors for persistent severe acute respiratory syndrome coronavirus 2 infection and construction of predictive models: an exploratory research study. BMC Infectious Diseases, [S. l.], v. 25, p. 699, 14 maio 2025. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC12080215/. Acesso em: 10 jan. 2026.
ZHANG, P. et al. Elevated interleukin-6 and adverse outcomes in COVID-19 patients: a meta-analysis based on adjusted effect estimates. Immunogenetics, [S. l.], v. 72, n. 8, p. 431–437, out. 2020.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2026 Amanda dos Santos de Amorim, Evailson Ferreira Porto, Caroline Tianeze de Castro, Fabrício Freire de Melo, Márcio Vasconcelos Oliveira
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Authors who publish in this journal agree to the following terms:
Authors retain copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Creative Commons Attribution License, which permits the sharing of the work with proper acknowledgment of authorship and initial publication in this journal;
Authors are authorized to enter into separate, additional agreements for the non-exclusive distribution of the version of the work published in this journal (e.g., posting in an institutional repository or publishing it as a book chapter), provided that authorship and initial publication in this journal are properly acknowledged, and that the work is adapted to the template of the respective repository;
Authors are permitted and encouraged to post and distribute their work online (e.g., in institutional repositories or on their personal websites) at any point before or during the editorial process, as this may lead to productive exchanges and increase the impact and citation of the published work (see The Effect of Open Access);
Authors are responsible for correctly providing their personal information, including name, keywords, abstracts, and other relevant data, thereby defining how they wish to be cited. The journal’s editorial board is not responsible for any errors or inconsistencies in these records.
PRIVACY POLICY
The names and email addresses provided to this journal will be used exclusively for the purposes of this publication and will not be made available for any other purpose or to third parties.
Note: All content of the work is the sole responsibility of the author and the advisor.
